Brick42
Brick42 is a leading provider of complex active ingredients (APIs) for the generic pharmaceutical industry, with a focus on high-quality APIs at competitive prices. The company is involved in advanced therapies research, manufacturing of APIs, and supporting innovative therapeutic projects. Brick42 operates in the US and Switzerland, with a strong commitment to supporting the development and accessibility of generic and advanced therapeutic drugs.
Industries
Nr. of Employees
small (1-50)
Products
Eribulin API (microtubule-inhibitor oncology API)
Synthetic, non-infringing process for production of the oncology microtubule-inhibitor API; available for commercial inquiry.
Lurbinectedin API (small-molecule oncology API)
Fully developed synthetic process for production of the oncology API including novel crystalline forms.
Trabectedin API (anti-tumor small-molecule API)
Fully developed synthetic, non-infringing process for production of a marine-derived anti-tumor API; offering available as API only or API plus finished dosage form.
Trametinib API (MEK inhibitor API)
Development of a non-infringing synthetic process for the MEK-inhibitor API for oncology indications; available for inquiry.
Nusinersen-related oligonucleotide API capabilities
Technical expertise and research activity related to oligonucleotide therapeutics exemplified by nusinersen; includes analytical method work relevant to generic development.
Collagenase API
Development work toward an enzyme API (collagenase) intended for medical and research uses.
Eribulin API (microtubule-inhibitor oncology API)
Synthetic, non-infringing process for production of the oncology microtubule-inhibitor API; available for commercial inquiry.
Lurbinectedin API (small-molecule oncology API)
Fully developed synthetic process for production of the oncology API including novel crystalline forms.
Trabectedin API (anti-tumor small-molecule API)
Fully developed synthetic, non-infringing process for production of a marine-derived anti-tumor API; offering available as API only or API plus finished dosage form.
Trametinib API (MEK inhibitor API)
Development of a non-infringing synthetic process for the MEK-inhibitor API for oncology indications; available for inquiry.
Nusinersen-related oligonucleotide API capabilities
Technical expertise and research activity related to oligonucleotide therapeutics exemplified by nusinersen; includes analytical method work relevant to generic development.
Collagenase API
Development work toward an enzyme API (collagenase) intended for medical and research uses.
Services
Commercial supply of complex APIs (high-potency small molecules, oligonucleotides, biologics, enzymes) to generic and specialty pharmaceutical manufacturers.
Development of synthetic, non-infringing manufacturing routes and solid-form optimization for oncology and other complex small-molecule APIs; can be coupled to scale-up and supply.
Analytical R&D targeted at oligonucleotide-specific challenges, including methods to demonstrate equivalence and control stereochemical or diastereomeric attributes.
Supply and GMP manufacture of nucleoside monomers, nucleotides, modified nucleosides, and triphosphates, plus customized oligonucleotides via partner network.
Development programs for protein-based therapeutics and enzyme APIs, including preclinical development and API supply for clinical or commercial use.
Collaborative research and development services for novel therapeutic modalities, including boron-based compounds, nanoparticle delivery for BNCT, and conjugate therapeutics.
Commercial supply of complex APIs (high-potency small molecules, oligonucleotides, biologics, enzymes) to generic and specialty pharmaceutical manufacturers.
Development of synthetic, non-infringing manufacturing routes and solid-form optimization for oncology and other complex small-molecule APIs; can be coupled to scale-up and supply.
Analytical R&D targeted at oligonucleotide-specific challenges, including methods to demonstrate equivalence and control stereochemical or diastereomeric attributes.
Supply and GMP manufacture of nucleoside monomers, nucleotides, modified nucleosides, and triphosphates, plus customized oligonucleotides via partner network.
Development programs for protein-based therapeutics and enzyme APIs, including preclinical development and API supply for clinical or commercial use.
Collaborative research and development services for novel therapeutic modalities, including boron-based compounds, nanoparticle delivery for BNCT, and conjugate therapeutics.
Expertise Areas
- Generic API manufacturing
- High-potency API production and containment
- Oligonucleotide therapeutics development
- Nucleoside chemistry and supply
Key Technologies
- Oligonucleotide synthesis (antisense and related modalities)
- Nucleoside and nucleotide production (monomers and triphosphates)
- HPAPI containment and handling systems
- Small-molecule synthetic process development